SCHEMBL4834837

SCHEMBL4834837

CC(C)(C)OC(=O)N1CCN(C2(CN)Cc3ccccc3C2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.46
CHRM4 P08173 1/20 0.46
CHRM1 P11229 1/20 0.46
CHRM3 P20309 1/20 0.46
MAPK1 P28482 1/20 0.45
NAMPT P43490 3/20 0.45
GPR119 Q8TDV5 1/20 0.43
DTYMK P23919 1/20 0.43
KDM4E B2RXH2 1/20 0.42
PKM P14618 1/20 0.42
POLB P06746 1/20 0.41
SMARCA2 P51531 1/20 0.41
SMARCA4 P51532 1/20 0.41
PBRM1 Q86U86 1/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
CKS1B P61024 1/20 0.41
SKP1 P63208 1/20 0.41
SKP2 Q13309 1/20 0.41
OPRD1 P41143 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4830166 0.89 CHRM2 (0.46) CHRM2CHRM4CHRM1CHRM3MAPK1
SCHEMBL14314358 0.85 CHRM2 (0.44) CHRM2CHRM4CHRM1CHRM3MAPK1
SCHEMBL22441592 0.81 USP2 (0.46) CHRM2CHRM4CHRM1CHRM3KMT2A
SCHEMBL27732317 0.81 LIPG (0.46) CHRM2CHRM4CHRM1CHRM3MAPK1
SCHEMBL4832307 0.80 GPR119 (0.48) CHRM2CHRM4CHRM1CHRM3MAPK1
SCHEMBL18458221 0.78 OPRD1 (0.53) CHRM2CHRM4CHRM1CHRM3MAPK1
SCHEMBL25219480 0.78 USP2 (0.50) CHRM2CHRM4CHRM1CHRM3KMT2A
SCHEMBL13587114 0.78 USP2 (0.43) NAMPTKMT2AOPRD1OPRK1GAA
SCHEMBL14306308 0.78 MAPK1 (0.45) CHRM2CHRM4CHRM1CHRM3MAPK1
SCHEMBL29609790 0.76 MAPK1 (0.51) CHRM2CHRM4CHRM1CHRM3MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7442692-B2 Indanyl-piperazine compounds LES LABORATOIRES SERVIER (FR) 2008-10-28 US disclosed
WO-2006103342-A9 INDANYL-PIPERAZINE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SERVIER LAB (FR) 2007-10-25 WO disclosed
EP-1707564-B1 Indanyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2007-09-12 EP disclosed
US-20060223830-A1 Indanyl-piperazine compounds LES LABORATOIRES SERVIER (FR) 2006-10-05 US disclosed
WO-2006103342-A2 INDANYL-PIPERAZINE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME LES LABORATOIRES SERVIER (FR) 2006-10-05 WO disclosed
EP-1707564-A2 Indanyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2006-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223830-A1 Indanyl-piperazine compounds HTR4, NR4A1, NR4A3 CHRM2 146/4885CHRM4 50/4885CHRM1 141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.